How did VYGR's Q4 2024 earnings surprise impact its annual performance?

Voyager Therapeutics' (VYGR) Q4 2024 earnings surprise had a significant impact on its annual performance, reflecting the company's ongoing challenges and the broader implications for its financial outlook.

1. **Q4 Earnings Surprise**:
- Voyager Therapeutics reported an earnings per share (EPS) surprise of -$0.22 for Q4 2024.
- This negative surprise indicates that the actual EPS fell short of market expectations by $0.22, suggesting weaker-than-anticipated financial performance for the quarter.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|VYGR|VYGR.O|Voyager Therapeutics|2024 Q1|-109.13385572861243|-1.133E7|185|
|VYGR|VYGR.O|Voyager Therapeutics|2024 Q2|54.33627521613833|-1.0141E7|185|
|VYGR|VYGR.O|Voyager Therapeutics|2024 Q3|65.08242924983591|-9044000|185|
|VYGR|VYGR.O|Voyager Therapeutics|2024 Q4|-161.15258444897597|-3.4487E7|185|

2. **Annual Net Income Impact**:
- Despite the Q4 surprise, Voyager Therapeutics incurred a total net loss of approximately -$65 million for the full year 2024.
- The Q4 surprise of -$0.22, when compounded across all four quarters, would further contribute to the annual net loss, highlighting the severity of the company's financial struggles.

In summary, Voyager Therapeutics' Q4 2024 earnings surprise, though negative, was part of a larger annual loss, indicating that while it may have been a disappointment, it did not occur in isolation, and the company's overall financial health remains a significant concern.